valproic acid has been researched along with etoposide in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 14 (42.42) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Batrakova, EV; Kabanov, AV; Li, S; Miller, DW | 1 |
| Bourg, V; Chichmanian, RM; Frenay, M; Lebrun, C; Thomas, P | 1 |
| Ikeda, H; Kihira, K; Murakami, T; Takano, M; Usui, T | 1 |
| Koistinen, P; Savolainen, ER; Siitonen, T | 1 |
| Bernardini, S; Federici, G; Gravina, P; Valentini, A | 1 |
| Aguilera, D; Das, CM; Gopalakrishnan, V; Prasad, P; Vasquez, H; Wolff, JE; Zhang, M | 1 |
| Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; de Grazia, U; Salmaggi, A | 1 |
| Fritsche, P; Göttlicher, M; Saur, D; Schmid, RM; Schneider, G; Schnieke, A; Schüler, S; Seidler, B | 1 |
| Füllgrabe, J; Hajji, N; Hermanson, O; Joseph, B; Vlachos, P; Wallenborg, K | 1 |
| Albelda, SM; Burny, A; Crisanti, C; Crisanti, MC; Hubaux, R; Kapoor, V; Mascaux, C; Vandermeers, F; Willems, L | 1 |
| Aguilera, D; Das, CM; Gopalakrishnan, V; Lee, D; Taylor, P; Wolff, JE; Zage, PE | 1 |
| Jasek, E; Jasinska, M; Jurkowska, H; Lis, GJ; Litwin, JA | 1 |
| Eckschlager, T; Groh, T; Hrabeta, J; Poljakova, J; Stiborova, M | 1 |
| Doktorova, H; Eckschlager, T; Groh, T; Hrabeta, J; Khalil, MA; Stiborova, M | 1 |
| Abrari, A; Gupta, A; Kumar, A; Patir, R; Vaishya, S | 1 |
| Fan, L; Jiang, T; Qiu, X; Yin, Y; Zhu, Q | 1 |
| Chuang, YJ; Liu, LY; Shyu, YM | 1 |
| Barathi, D; Dahagama, S; Dubashi, B; Ganesan, P; Goenka, L; Kayal, S; Krishnamoorthy, N; Mathaiyan, J; Nakka, T; Thumaty, DB | 1 |
2 review(s) available for valproic acid and etoposide
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for valproic acid and etoposide
| Article | Year |
|---|---|
Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Communicable Disease Control; COVID-19; Cytotoxins; Etoposide; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lymphoma, Follicular; Middle Aged; Ovarian Neoplasms; Prospective Studies; Sodium; Valproic Acid | 2022 |
30 other study(ies) available for valproic acid and etoposide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.
Topics: Animals; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Caco-2 Cells; Cattle; Contrast Media; Doxorubicin; Drug Resistance, Neoplasm; Endothelium, Vascular; Enzyme Inhibitors; Etoposide; Excipients; Fluorescein; Humans; Intestinal Absorption; Loperamide; Micelles; Microcirculation; Paclitaxel; Poloxamer; Tritium; Valproic Acid; Zidovudine | 1999 |
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Drug Interactions; Epilepsy; Etoposide; Female; Glioma; Hematologic Tests; Humans; Male; Middle Aged; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Retrospective Studies; Thrombocytopenia; Valproic Acid | 2001 |
Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient.
Topics: Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Interactions; Epilepsy; Etoposide; Humans; Male; Recurrence; Testicular Neoplasms; Valproic Acid | 2005 |
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Topics: Butyrates; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Enzyme Inhibitors; Etoposide; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Valproic Acid | 2005 |
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Etoposide; Genes, p16; Humans; Melanoma; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Up-Regulation; Valproic Acid | 2007 |
Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Inhibitors; Etoposide; Gene Expression Regulation, Neoplastic; Glioblastoma; Histone Deacetylase Inhibitors; Histones; Humans; Isoenzymes; Valproic Acid | 2007 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Etoposide; Glioblastoma; Humans; Mitoxantrone; Valproic Acid | 2007 |
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gene Expression Profiling; Gene Silencing; Histone Deacetylase 2; Histone Deacetylases; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Valproic Acid | 2009 |
Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Topics: Acetylation; Animals; Cell Death; Cell Line, Tumor; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Histone Acetyltransferases; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lysine; Male; Neoplasms; Sirtuin 1; Topoisomerase II Inhibitors; Valproic Acid | 2010 |
Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Etoposide; Female; Gene Expression; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, SCID; Microarray Analysis; Neoplasm Transplantation; Small Cell Lung Carcinoma; Transplantation, Heterologous; Valproic Acid | 2010 |
Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Chromatin Immunoprecipitation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Synergism; Epigenomics; Etoposide; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Neuroblastoma; Valproic Acid | 2010 |
Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Caspase 7; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Leukemia; Membrane Potential, Mitochondrial; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; U937 Cells; Valproic Acid | 2012 |
Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Neoplasms; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; Humans; Neuroblastoma; Risk Factors; Valproic Acid | 2012 |
The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Topics: Acetylation; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Synergism; Etoposide; Histone Deacetylase Inhibitors; Histones; Humans; Neuroblastoma; Valproic Acid | 2015 |
Successful Use of Dose Dense Neoadjuvant Chemotherapy and Sodium Valproate with Minimal Toxicity in an Infant with Medulloblastoma in Extremely Poor General Condition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Child; Child, Preschool; Critical Care; Cyclophosphamide; Drug Administration Schedule; Etoposide; Histone Deacetylase Inhibitors; Humans; Infant; Longitudinal Studies; Male; Medulloblastoma; Neoadjuvant Therapy; Neurocognitive Disorders; Neurodevelopmental Disorders; Treatment Outcome; Valproic Acid; Vincristine | 2016 |
Targeting histones for degradation in cancer cells as a novel strategy in cancer treatment.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; Drug Therapy, Combination; Etoposide; Gamma Rays; Histone Deacetylase Inhibitors; Histones; Homeostasis; Humans; Hydroxamic Acids; Methyl Methanesulfonate; Mice; Valproic Acid; Vorinostat | 2019 |
Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Melanoma; Valproic Acid | 2021 |